Authors

Latest:

New Cancer Study Results Confirm Lasting Effects on 9/11 First Responders

Research investigating the physical and mental health consequences of being at the World Trade Center site during and after the terrorist attacks has been instrumental in obtaining health care coverage for thousands of individuals.

Sidney Kimmel Cancer Center – Jefferson Health

Latest:

SKCC’s Dr. Edith Mitchell Named Enterprise Vice President for Cancer Disparities

Edith P. Mitchell, MD, MACP, FCCP, FRCP, Director of the Center to Eliminate Cancer Disparities and Clinical Professor of Medicine and Medical Oncology, has been named Enterprise Vice President for Cancer Disparities at Jefferson Health’s Sidney Kimmel Cancer Center.

Mario Spaggiari, MD

Latest:

Dr. Spaggiari on Surgical Strategies to Improve Liver Remnants in CRC With Liver Metastases

Mario Spaggiari, MD, discusses surgical strategies to improve liver remnants in colorectal cancer with liver metastases.

Jordyn Sava

Latest:

Consolidation Benmelstobart ± Anlotinib Provides Substantial PFS Benefits in Stage III NSCLC

Benmelstobart with or without anlotinib boosted progression-free survival after chemoradiotherapy in unresectable stage III non–small cell lung cancer.

Roger Li, MD

Latest:

Dr Li on Progression Risk in Low-Grade NMIBC and the Emerging Role of AI-Based Pathology Assessment

Roger Li, MD, discusses progression risk in low-grade NMIBC and how AI-based pathology tools may improve identification of patients at risk for high-grade disease.

Jyoti Mayadev, MD

Latest:

Dr Mayadev on Using PD-L1 TAP as a Predictive Biomarker for Locally Advanced Cervical Cancer

Jyoti Mayadev, MD, discusses the clinical significance of tumor area positivityas a predictive biomarker in locally advanced cervical cancer.

Fernando C. Santini, MD

Latest:

Emerging Antibody Drug Conjugates in the Lung Cancer Treatment Landscape

Dr Martin Dietrich gives an overview of novel antibody-drug conjugates in the NSCLC treatment landscape.

Chandler Park, MD, MSc, FACP

medical oncologist, Norton Healthcare

Latest:

Catching Up on the Latest Data in CLL and Lymphoma With Drs Emmons, Brody, and Pinilla

Robert Emmons, MD, FACP, Joshua Brody, MD, and Javier Pinilla, MD, PhD, sit down with Chandler Park, MD, FACP, to discuss the latest abstracts in chronic lymphocytic leukemia and lymphoma presented during the 2025 ASH Annual Meeting & Exposition.

Boris A. Hadaschik, MD

Latest:

Dr. Hadaschik on Treatment After Apalutamide Progression in SPARTAN Trial

Boris A. Hadaschik, MD, discusses a post-hoc analysis of subsequent therapies received by patients with prostate cancer treated with apalutamide during the phase 3 SPARTAN trial.

Thomas Martin, MD, University of California San Francisco

Latest:

Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma Patients With High-Risk Cytogenetics: IKEMA Subgroup Analysis

Expert hematologist-oncologist Thomas G. Martin, MD, shares data from the IKEMA subgroup analysis in patients with relapsed multiple myeloma treated with isatuximab, carfilzomib, and dexamethasone.

Regis Peffault de Latour, MD, PhD

Latest:

Dr Peffault de Latour on the Benefit of Iptacopan Vs SOC in PNH and Residual Anemia

Regis Peffault de Latour, MD, PhD, discusses the benefit observed with iptacopan vs standard-of-care eculizumab or ravulizumab in patients with paroxysmal nocturnal hemoglobinuria and residual anemia during the phase 3 APPLY-PNH trial.

Mark Geyer, MD

Latest:

Ponatinib-Based Regimens Strengthen the Ph+ ALL Treatment Paradigm: With Mark B. Geyer, MD, and Elias Jabbour, MD

Drs Geyer and Jabbour discuss ponatinib in Ph+ ALL, data with this agent plus blinatumomab, and how the safety profile of ponatinib affects its use.

Noah Merin, MD, PhD

Latest:

Real World Data on the Use of Ruxolitinib and Treatment Selection in chronic GvHD

Discussion centered around real-world data following the approval of ruxolitinib as a treatment option for patients with chronic GvHD as well as discussing treatment selection for patients with chronic GvHD, with special consideration for treatment sequencing.

Mikkael A. Sekeres, MD, MS, Sylvester Comprehensive Cancer Center

Mikkael A. Sekeres, MD, is a professor of medicine and chief of the Division of Hematology, in the Leukemia Section, at the Sylvester Comprehensive Cancer Center, University of Miami Health System.

Latest:

Dr Sekeres on the Impact of BTK Inhibitors on Approaches to CLL Management

Mikkael A. Sekeres, MD, discusses how the emergence of BTK inhibitors have shifted approaches to the management of chronic lymphocytic leukemia.

Darren Pan, MD

Darren Pan, MD, is an assistant professor of Medicine at the University of California, San Francisco School of Medicine.

Latest:

Dr Pan on Late-Onset Toxicities Associated With CAR T-Cell Therapy in Multiple Myeloma

Darren Pan, MD, outlines late-onset toxicities related to CAR T-cell therapies in multiple myeloma and their management.

Steven L. Spitalnik, MD

Latest:

Dr. Spitalnik on Goals for the Hemanext® Blood Storage System in Hematologic Malignancies

Steven L. Spitalnik, MD, discusses the goals for the Hemanext® blood storage system in patients with hematologic malignancies.

Zev A. Wainberg, M.D. Professor of Medicine at UCLA and co-director of the UCLA GI Oncology Program

Latest:

Improving outcomes in metastatic pancreatic cancer

Pancreatic cancer remains elusive with extremely low survival rates. Through better utilization of existing therapies and identifying patient subgroups, some believe we are incrementally improving patient outcomes and making more significant advances in care.

Nan Chen, MD

Latest:

Dr Chen on the Evolution of Novel Therapies in Breast Cancer

Dawn L. Hershman, MD, Herbert Irving Comprehensive Cancer Center at Columbia University

Latest:

Rapid Readouts: Updated Results From KX-ORAX-001 Study

George Simon, MD, FACP, FCCP

Latest:

Dr Simon on the Utility of Novel Treatments in Diverse Patient Populations With Cancer

George Simon, MD, FACP, FCCP, discusses the importance of enrolling diverse patient populations in cancer clinical trials.